Blueprint Medicines Corporation (BPMC)

NASDAQ: BPMC · IEX Real-Time Price · USD
97.04
-2.75 (-2.76%)
Feb 28, 2024, 3:11 PM EST - Market open
-2.76%
Market Cap 6.02B
Revenue (ttm) 249.38M
Net Income (ttm) -506.98M
Shares Out 61.23M
EPS (ttm) -8.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 585,381
Open 98.15
Previous Close 99.79
Day's Range 96.51 - 101.00
52-Week Range 40.48 - 100.98
Beta 0.61
Analysts Buy
Price Target 85.87 (-11.51%)
Earnings Date Feb 15, 2024

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2015
Employees 655
Stock Exchange NASDAQ
Ticker Symbol BPMC
Full Company Profile

Financial Performance

In 2023, BPMC's revenue was $249.38 million, an increase of 22.22% compared to the previous year's $204.04 million. Losses were -$506.98 million, -9.06% less than in 2022.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $85.87, which is a decrease of -11.51% from the latest price.

Price Target
$85.87
(-11.51% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial ...

5 days ago - PRNewsWire

Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results

-- Achieved $204.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approxi...

13 days ago - PRNewsWire

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , Feb. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024, the Compensation Committee of Blueprint Medicines' Boa...

22 days ago - PRNewsWire

Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

27 days ago - PRNewsWire

VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug Discovery

BOSTON--(BUSINESS WIRE)--VantAI, a leader in the fields of drug discovery and generative AI, announced today it has entered into an amended and restated collaboration and license agreement with Bluepr...

7 weeks ago - Business Wire

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference

-- AYVAKIT® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. launch and recent EU approval -- -- Expanding mast cell disease leadership ...

7 weeks ago - PRNewsWire

Biotech stocks set for a rebound in 2024, analysts say

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

2 months ago - Market Watch

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 ...

2 months ago - PRNewsWire

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

-- In the European Union, patients with indolent systemic mastocytosis now have an approved medicine that treats the primary driver of disease  -- -- Approval based on data from PIONEER trial, in whic...

2 months ago - PRNewsWire

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM fra...

2 months ago - PRNewsWire

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass. , Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securit...

3 months ago - PRNewsWire

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis

-- For the first time, the estimated 40,000 patients with indolent SM in the EU 1,2* would have a medicine that treats the primary disease driver 3,4  -- -- Opinion based on the positive PIONEER trial...

3 months ago - PRNewsWire

Blueprint Medicines Reports Third Quarter 2023 Results

-- Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 – -- Approxi...

4 months ago - PRNewsWire

Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023

CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

4 months ago - PRNewsWire

Blueprint Medicines Reports Second Quarter 2023 Results

-- Achieved $39.9 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 -- -- AYVAKIT approved by the FDA for the treatment ...

7 months ago - PRNewsWire

Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

8 months ago - PRNewsWire

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

-- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs -- CAMBRIDGE, Mass. , June 3, 2023 /PRNews...

9 months ago - PRNewsWire

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis

-- First and only treatment approved by FDA for indolent SM -- CAMBRIDGE, Mass. , May 23, 2023  /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a jou...

10 months ago - PRNewsWire

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

-- For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief -- -- Approval based on the positive P...

10 months ago - PRNewsWire

Blueprint Medicines Reports First Quarter 2023 Results

-- Achieved $39.1 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 -- -- Raising 2023 AYVAKIT net product revenue guidan...

10 months ago - PRNewsWire

Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting

CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy...

11 months ago - PRNewsWire

Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

CAMBRIDGE, Mass. , April 20, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

11 months ago - PRNewsWire

Blueprint Medicines to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its participation in the following upcoming investor conferences:

11 months ago - PRNewsWire

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222

CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on ...

1 year ago - PRNewsWire

Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

-- AYVAKIT achieved a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, with improvements shown across all individual symptoms -- -- AYVAK...

1 year ago - PRNewsWire